Humanitarian device

Epicel (cultured epidermal autografts) is authorized for use in adult and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%. It may be used in conjunction with split-thickness autografts, or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns. The effectiveness of the device for this use has not been demonstrated.

Important Safety Information

Epicel is contraindicated in patients with a history of anaphylaxis following exposure to vancomycin, amikacin, and amphotericin, as trace quantities of these anti-infective agents may remain in the Epicel autograft. Epicel should not be used in patients with known sensitivities to materials of bovine or murine origin. It is contraindicated for use on clinically infected wounds.

Epicel product

Epicel is an autologous treatment for adult and pediatric patients with deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%

Autologous treatment:

Burn repair using a patient's own cells

A customized amount of Epicel grafts can be generated and shipped to your facility in a single order

A Vericel representative is available to help determine the appropriate use and number of grafts per patient.

Epicel is derived from two full-thickness biopsies measuring approximately 6cm long by 2cm wide. 

Skin graft dimensions - 6cm x 2cm

Epicel is permanent skin covering for burns ≥30% TBSA

Epicel Patient Survival

In the Epicel Clinical Experience databases, 954 adult and pediatric patients with a mean TBSA of 67.5% showed:

84.4% survival¹

The overall survival rate was 84.4% (804/954) at hospital discharge.
The survival rate for pediatric patients was 88.9% and for adults the survival rate was 82.0%.1

Burn patient survival In the 2016 National Burn Repository, 8,870 burn patients with a TBSA of 30%-90% showed: 68% survival2

A single Epicel order can cover an area up to

5,760 cm2 Epicel can be ordered for subsequent surgeries without the need for additional biopsies

In the Epicel Clinical Experience databases, 453 patients showed a median take rate at discharge of 75%1

Additional potential benefits of Epicel have been reported:

Rapid Wound

Epicel may assist in establishing a more rapid wound closure3


Epicel is able to maintain the characteristics of authentic epidermis4

Lower Rate of Infection

By facilitating early wound closure, Epicel was shown to lower the postoperative infection rate5


The Epicel Experience:
One Burn Center's Practice*

*Paid testimonial by an Epicel patient. Individual results may vary.

History of Excellence

Epicel has been used for over 25 years and is manufactured in a state-of-the-art cell culturing facility in Cambridge, Massachusetts

Verified and Validated

Epicel is evaluated for cell sterility and viability, verified by a standard assessment, and then confirmed prior to shipment

Expert support Provided

Vericel Account Managers and Burn Clinical Specialists are dedicated to providing support for healthcare teams using Epicel

Burns constitute a significant expense

Epicel may lower the rate of postoperative infection as well as shorten the hypermetabolic response to the burn injury, which may lead to faster wound closure and reduced overall stay.4,6

Mean number of hospital days by TBSA in surviving patients2
%TBSA by Hospital Days
Mean cost of hospital stay by TBSA in surviving patients2
%TBSA by Hospital Charges (in thousands)

Specialists are available to answer reimbursement questions about Epicel and the CEA procedure.

Epicel is widely reimbursed and included on a majority of national insurance plans.
Click here to learn more about Epicel reimbursement